Wayne-based prescription dermatology developer Cutanea Life Sciences is taking a unique new acne treatment on the road — both literally and figuratively.
Cutanea has sent out a 16-strong sales force for its debut product, Aktipak, which was designed to do what few of its competitors can do: be taken on the go at room temperature and last more than a year rather than a month, according to a Philadelphia Business Journal report by John George.
“They have already hit the ground, in terms of getting their physician customers acquainted with who we are,” said CEO Bob Bitterman Sr. of his salespeople.
The topical gel made of an antibiotic and benzoyl peroxide is ready to take on the nation’s most common skin condition, which affects 50 million people in a $3 billion industry.
“Our parent company would probably be happy if we got 10 percent (market share),” Bitterman said. “I’d like more.”
Beyond the acne treatment, Cutanea is also working on solutions for psoriasis, rosacea, atopic dermatitis, and warts from human papillomavirus.
Read more about Cutanea and its Aktipak in the Philadelphia Business Journal here.